Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity

Oncogene volume 23, pages 7144–7148 (2004)Cite this article

Abstract

Mutation of the APC tumor suppressor gene is one of the earliest events in the development of most colorectal tumors. The APC gene encodes multiple protein isoforms through a complicated pattern of expression and alternative splicing. The role that each isoform plays in cellular physiology is unknown, although the presence of some of these isoforms in postmitotic cells suggests a role in controlling cell growth or promoting differentiation. Three APC isoforms that differ in their amino-terminal domains were evaluated by gene transfer experiments using a colon cancer cell line that lacks functional APC. All three isoforms alter cellular morphology and affect cell growth by elongating the G1 phase of the cell cycle. The conventional APC and brain-specific APC isoforms suppress the tumorigenic phenotype of cultured cells, while the 0.3 APC isoform does not. In support of these experiments, BrdU incorporation as a marker for S-phase entry occurs at a higher level in transiently transfected cells with 0.3 APC when compared to cells transfected with the other isoforms. All three APC isoforms colocalize with microtubules and dramatically reduce β-catenin activity to the same extent in transiently transfected cancer cells, suggesting that the different effects of each isoform on tumorigenesis may be nontranscriptional in origin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W . (1996). Nature, 382, 638–642.

  • Goss KH and Groden J . (2000). J. Clin. Oncol., 18, 1967–1979.

  • Gossen M and Bujard H . (1992). Proc. Natl. Acad. Sci. USA, 89, 5547–5551.

  • Groden J, Joslyn G, Samowitz W, Jones D, Bhattacharyya N, Spirio L, Thliveris A, Robertson M, Egan S, Meuth M and White R . (1995). Cancer Res, 55, 1531–1539.

  • Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Crapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmoth J, Le Paslier D, Abderrahim, H, Cohen D, Leppert M and White R . (1991). Cell, 66, 589–600.

  • Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T and Groden J . (2002). Gastroenterology, 123, 751–763.

  • Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG and Kemler R . (1996). Mech. Dev., 59, 3–10.

  • Joslyn G, Richardson DS, White R and Alber T . (1993). Proc. Natl. Acad. Sci. USA, 90, 11109–11113.

  • Kinzler KW and Vogelstein B . (1996). Cell, 87, 159–170.

  • Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B and Polakis P . (1994). Cancer Res., 54, 3676–3681.

  • Pyles RB, Santoro IM, Groden J and Parysek LM . (1998). Oncogene, 16, 77–82.

  • Santoro IM and Groden J . (1997). Cancer Res., 57, 488–494.

  • Smith KJ, Levy DB, Maupin P, Pollard TD, Vogelstein B and Kinzler KW . (1994). Cancer Res., 54, 3672–3675.

  • Su LK, Johnson KA, Smith KJ, Hill DE, Vogelstein B and Kinzler KW . (1993). Cancer Res., 53, 2728–2731.

Download references

Acknowledgements

We thank J Cornelius for flow cytometric analyses, M Medvedovic for statistical assistance and B Hennigan for assistance with confocal microscopy. We also thank H Baribault for the TROMA-1 antibody and JC Bulinski for the anti-Tyr antisera. JG is an Investigator with the Howard Hughes Medical Institute. This work was supported by CA-63057 (JG) and T32-DK-64581-1 (DC).

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Biochemistry and Microbiology, Howard Hughes Medical Institute, University of Cincinnati College of Medicine, Cincinnati, 45267, OH, USA

    Daniel J Carson, Irma M Santoro & Joanna Groden

Authors
  1. Daniel J Carson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irma M Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joanna Groden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanna Groden.

Additional information

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with USC Section 1734 solely to indicate this fact

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carson, D., Santoro, I. & Groden, J. Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity. Oncogene 23, 7144–7148 (2004). https://doi.org/10.1038/sj.onc.1207954

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207954

Keywords

This article is cited by

Search

Advanced search

Quick links